DermaRite Industries Faces Class I Recall for DermaSarra External Analgesic Due to Burkholderia cepacia Contamination
DermaRite Industries, LLC initiated a Class I recall (D-0611-2025) for 249 bottles of DermaSarra External Analgesic (Camphor 0.5%) due to contamination with *Burkholderia cepacia*. This nationwide recall, impacting Lot #: 40187.2, signals critical quality control failures. Procurement and regulatory teams must assess supply chain risks and ensure robust microbial testing protocols for non-sterile drug products to mitigate patient safety threats.
FDA Mandates Class I Recall for DermaRite's DermaSarra Due to Microbial Contamination
DermaRite Industries, LLC has initiated a Class I recall, identified as D-0611-2025, impacting 249 bottles of its DermaSarra External Analgesic (Camphor 0.5%). This critical action, voluntarily undertaken by the firm but overseen by the FDA, stems from the detection of *Burkholderia cepacia* bacteria within the non-sterile drug product. The affected product, specifically Lot #: 40187.2 with an expiration date of February 2026, is packaged in 222 mL (7.5 fl. oz.) bottles and carries the NDC 61924-189-08. This recall, initiated on July 17, 2025, and classified by the FDA on September 2, 2025, signifies the highest level of risk, indicating that use of the product could lead to serious adverse health consequences or even death. For procurement directors, this event necessitates an immediate audit of existing inventory and supply chains for DermaSarra and any similar external analgesic products sourced from DermaRite Industries, LLC's facility at 7777 W Side Ave, North Bergen, NJ 07047-6436. Regulatory affairs heads must assess the implications for product registration and market availability, while supply chain VPs face the immediate challenge of managing potential shortages and ensuring the safe return or disposal of contaminated stock distributed nationwide within the USA. This incident underscores the critical importance of robust quality control in non-sterile pharmaceutical manufacturing.
Critical Patient Safety and Supply Chain Risks from Burkholderia cepacia Contamination
The presence of *Burkholderia cepacia* in DermaSarra External Analgesic poses a significant and immediate threat, justifying the Class I recall classification. *Burkholderia cepacia* is an opportunistic pathogen known to cause serious infections, particularly in vulnerable populations such as immunocompromised individuals, patients with cystic fibrosis, or those with chronic lung diseases. For business development executives, this contamination event highlights the severe reputational and financial repercussions that can arise from quality failures, potentially impacting market trust and future product launches. Procurement directors must recognize that even non-sterile drug products require stringent microbial control, as external applications can still lead to systemic infections, especially when applied to compromised skin. The nationwide distribution pattern within the USA means that the risk is widespread, requiring a coordinated response across all affected distribution channels. Supply chain VPs must prioritize rapid identification and quarantine of all affected Lot #: 40187.2 units to prevent further patient exposure. This incident serves as a stark reminder for regulatory affairs heads to review and reinforce their microbial testing protocols, environmental monitoring programs, and supplier qualification processes, particularly for products manufactured at facilities like DermaRite Industries, LLC's North Bergen site, to proactively mitigate such high-severity risks.
Regulatory Compliance and Remediation Expectations Following DermaRite's Recall
The firm-initiated nature of DermaRite Industries, LLC's recall indicates that the company identified the microbial contamination internally, a critical first step in managing such a crisis. However, with the recall status currently 'Ongoing,' the FDA will be closely monitoring DermaRite's remediation efforts. For regulatory affairs heads, this means a comprehensive investigation into the root cause of the *Burkholderia cepacia* contamination is paramount, encompassing raw material quality, manufacturing processes, environmental controls, and personnel practices at the North Bergen facility. The FDA expects robust Corrective and Preventive Actions (CAPA) to be implemented and verified for effectiveness. This situation parallels other recent regulatory challenges, such as Essential Wellness Pharma's Class II recall for sterility assurance failures, underscoring the FDA's heightened scrutiny on microbial control across the pharmaceutical sector. Business development executives should anticipate increased regulatory oversight for non-sterile drug products, potentially leading to more rigorous pre-market approvals and post-market surveillance. Procurement directors must ensure that their supplier agreements include provisions for immediate notification of such events and detailed remediation plans. Supply chain VPs should prepare for potential delays in product availability as DermaRite works to address the underlying issues and restore compliance, emphasizing the need for diversified sourcing strategies to maintain supply continuity.